Context Therapeutics Is On The Rise, Stock Soars 50%

Data from the Context Therapeutics Phase 2 clinical trial of onatapristone extended release for the treatment of postmenopausal women with early breast cancer were presented at the San Antonio Breast Cancer Symposium in 2021. CNTX stock is rising 50% in the recent sessions, jumping to costing $8.11 per share.

The ONAWA trial was a multicenter, open-label study conducted at 10 centers in Spain to evaluate the safety, tolerability, and biological activity of ONA-XR in patients with ER+/HER2- negative breast cancer. The primary objective was to determine the percentage of patients with high levels of cell proliferation marker Ki67 (Ki67) and complete cell cycle arrest when administered three weeks prior to surgery.

Several patients didn’t get the CCR, at the same the other half of the patients had a decreased level of Ki67 in their condition. The disease with a high level of endocrine has made the patients trend and made the response come very close to the results.

The ONAWA trial showed that ONA-XR could help suppress the proliferation of breast cancer tumors and improve the overall prognosis of patients with early-stage breast cancer. The company’s ONA-XR program is currently being evaluated in four clinical trials for the treatment of hormone-driven cancers. Data from these trials have shown encouraging early evidence of the drug’s potential.